Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
---|
09/21/2005 | EP1575993A2 Methods for treating patients and identifying therapeutics |
09/21/2005 | EP1575916A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
09/21/2005 | EP1575673A2 Use of a trpm8-activating substance for the treatment of tumours |
09/21/2005 | EP1575658A2 Screening and therapeutic methods for treating circadian rhythm disorders |
09/21/2005 | EP1575618A2 Dispersible pharmaceutical compositions |
09/21/2005 | EP1575598A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
09/21/2005 | EP1575594A2 Combination of reboxetine and a cyclooxygenase-2 inhibitor |
09/21/2005 | EP1575590A1 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
09/21/2005 | EP1575583A1 Treatment of hiv infection through combined administration of tipranavir and capravirine |
09/21/2005 | EP1575582A1 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
09/21/2005 | EP1575580A2 Method of treating cancers |
09/21/2005 | EP1575579A2 Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents |
09/21/2005 | EP1575576A2 Organic compounds |
09/21/2005 | EP1575573A2 Agents and methods for treatment of disease by oligosaccharide targeting agents |
09/21/2005 | EP1575567A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
09/21/2005 | EP1575566A1 Multilayer dosage forms containing nsaids and triptans |
09/21/2005 | EP1575558A2 Ophthalmic and ophthalmological use of a complex nutritive base in an aqueous medium |
09/21/2005 | EP1575549A2 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid |
09/21/2005 | EP1575533A2 Topical compositions having a natural ingredient and method of use |
09/21/2005 | EP1575528A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
09/21/2005 | EP1575524A2 Proliferated cell lines and uses thereof |
09/21/2005 | EP1575519A2 Cd26-based therapies for cancers and immune disease |
09/21/2005 | EP1575504A2 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
09/21/2005 | EP1575499A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
09/21/2005 | EP1575497A2 Novel composition and methods for the treatment of psoriasis |
09/21/2005 | EP1575479A2 Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
09/21/2005 | EP1575379A1 Nutritional compositions |
09/21/2005 | EP1438038A4 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
09/21/2005 | EP1435965A4 Pharmaceutical compositions and methods for treating cancer |
09/21/2005 | EP1420790B1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
09/21/2005 | EP1401463B1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
09/21/2005 | EP1299382B1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
09/21/2005 | EP1282602B1 Propanoic acid derivatives as integrin receptor antagonists |
09/21/2005 | EP1263446B1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
09/21/2005 | EP1129188B1 Pge synthase and methods and means for modulating its activity |
09/21/2005 | EP1002065B1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
09/21/2005 | EP0996459B1 Use of exendins and agonists thereof for the reduction of food intake |
09/21/2005 | CN1671742A Use of HMGB1 in the treatment of tissue damage and/or to promote tissue repair |
09/21/2005 | CN1671734A CFTR modifier genes and expressed polypeptides useful in treating cystic fibrosis and methods and products for detecting and/or identifying same |
09/21/2005 | CN1671661A Aromatic sulfones and their medical use |
09/21/2005 | CN1671435A Medicament dispenser |
09/21/2005 | CN1671421A Inclusion complexes of rosiglitazone |
09/21/2005 | CN1671415A Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26 |
09/21/2005 | CN1671414A CpG formulations and related methods |
09/21/2005 | CN1671412A Immunostimulatory compositions and methods of stimulating an immune response |
09/21/2005 | CN1671407A Compositions and methods for treating diabetes |
09/21/2005 | CN1671399A Myocardial perfusion imaging using A2A receptor agonists |
09/21/2005 | CN1671397A Use of alkyl phosphocholines in combination with antitumor medicaments |
09/21/2005 | CN1671392A Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
09/21/2005 | CN1671391A Novel methods and compositions for alleviating pain |
09/21/2005 | CN1671390A Adenosine A2A receptor antagonists for treating restless legs syndrome or related disorders |
09/21/2005 | CN1671384A Methods of treating microbial infections in humans and animals |
09/21/2005 | CN1671379A Hydrazonopyrazole derivatives and their use as therapeutics |
09/21/2005 | CN1671376A Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent |
09/21/2005 | CN1671371A Combination of an aromatase inhibitor with a bisphosphonate |
09/21/2005 | CN1671370A Composition for solubilization of paclitaxel and preparation method thereof |
09/21/2005 | CN1671367A Aqueous 2, 6-diisopropylphenol pharmaceutical compositions |
09/21/2005 | CN1671365A Improved transdermal delivery system |
09/21/2005 | CN1671351A NSAID-containing topical formulations that demonstrate chemopreventive activity |
09/21/2005 | CN1669573A Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
09/21/2005 | CN1669554A Liposome vitality conazole preparation |
09/21/2005 | CN1220060C Process for screening active component from plant extract |
09/21/2005 | CN1219780C Heterocyclic compounds binding chemotactic factor receptor |
09/21/2005 | CN1219753C Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
09/21/2005 | CN1219510C Benzimidazole derivatives as modulators of IgE |
09/21/2005 | CN1219509C Use of rosmarinic acid and derivatives thereof as immunosuppressant or inhibitor of SHz-mediated process |
09/20/2005 | US6947845 Method of identifying molecules that bind to the large ribosomal subunit |
09/20/2005 | US6947844 Modulators of ribosomal function and identification thereof |
09/20/2005 | US6946548 Granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. |
09/20/2005 | US6946490 Medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution; for therapy |
09/20/2005 | US6946484 Controlling cancer by reducing its growth and improving response to therapy |
09/20/2005 | US6946476 For therapy of metabolic and eating disorders such as obesity and hyperphagia, diabetes |
09/20/2005 | US6946456 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction |
09/20/2005 | US6946444 Modify the activity of the lipolysis stimulated receptor and can be used to influence the partitioning of dietary lipids between the liver and peripheral tissues; treating obesity-related insulin resistance |
09/20/2005 | US6946441 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
09/20/2005 | US6946438 focal cerebral ischemic infarction; plasmin, mini-plasmin (lacking the first four kringles), and micro-plasmin (lacking all five kringles) |
09/20/2005 | US6946275 Human testis specific serine/threonine kinase 1 and 2 |
09/20/2005 | US6946259 Compositions and methods for treating cells having double minute DNA |
09/20/2005 | US6946244 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator |
09/20/2005 | US6946151 Therapeutic compositions |
09/20/2005 | US6946149 Salt solution for colon cleansing |
09/20/2005 | US6946141 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation |
09/20/2005 | US6946129 Recombinant anti-CD40 antibody and uses thereof |
09/20/2005 | US6946121 Composition in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method |
09/20/2005 | US6945247 Method of treating cardio pulmonary diseases with no group compounds |
09/20/2005 | CA2360649C Method of preparing particles for agglomeration |
09/20/2005 | CA2348869C Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents |
09/20/2005 | CA2285119C Retroviral protease inhibiting compounds |
09/20/2005 | CA2218549C Method to increase retinal blood flow |
09/20/2005 | CA2113515C Inhibiting the development of tolerance to and/or dependence on an addictive substance |
09/15/2005 | WO2005085846A1 Diagnostic for ischemic heart disease risk group |
09/15/2005 | WO2005085421A2 Treatment of spinal conditions |
09/15/2005 | WO2005085274A1 Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients |
09/15/2005 | WO2005085254A1 Process for inhibiting cell proliferation |
09/15/2005 | WO2005085241A1 Thiazole derivative |
09/15/2005 | WO2005085237A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
09/15/2005 | WO2005084727A1 Bone grafting material, comprising a porous carrier and at least one pyrrolindone, a method for its production and an implant |
09/15/2005 | WO2005084710A2 Nanocell drug delivery system |
09/15/2005 | WO2005084709A1 Remedy for urinary disorder |
09/15/2005 | WO2005084708A1 Medicinal composition containing cxcr3 inhibitor |